Ajanta Pharma Q1 FY27 profit up 31%, ₹32 dividend

What Ajanta Pharma reported for Q1 FY27

Ajanta Pharma Limited announced its consolidated financial results for the first quarter of FY2026-27 ended June 30, 2026, showing strong year-on-year growth across revenue and profit. Consolidated revenue from operations came in at ₹1,625.96 crore (about ₹1,626 crore), up 24.82% to 25% from ₹1,302.65 crore to ₹1,303 crore in Q1 FY26. Profit after tax (PAT) rose to ₹334 crore to ₹334.22 crore, representing 30.89% to 31% growth versus ₹255 crore to ₹255.34 crore a year ago. The company also announced a first interim dividend of ₹32 per equity share, signalling a meaningful cash return alongside earnings growth. The results were disclosed through exchange filings, with BSE cited as the source.

Revenue growth: ₹1,626 crore, up about 25%

The company’s top line expanded sharply in Q1 FY27, with consolidated revenue from operations reported at ₹1,625.96 crore. The comparable figure for Q1 FY26 was ₹1,302.65 crore, highlighting a year-on-year gain of 24.82%. In rounded terms, Ajanta Pharma also described revenue as increasing 25% to ₹1,626 crore from ₹1,303 crore. This level of expansion indicates broad-based traction, but the quarter’s narrative in the provided data points clearly to the US generics business as a key driver. The results also come at a time when investors have been closely tracking execution in export markets, especially the US, where price and product-cycle dynamics often determine quarterly volatility.

Profit after tax rises to ₹334 crore

Ajanta Pharma’s consolidated PAT rose to ₹334 crore to ₹334.22 crore in Q1 FY27 from ₹255 crore to ₹255.34 crore in Q1 FY26. The year-on-year rise of roughly 31% suggests operating leverage and a favourable business mix in the quarter. The provided data also expressed the Q1 FY27 net profit as 3.3B rupees versus 2.55B rupees a year ago, which corresponds to about ₹330 crore versus ₹255 crore when translated to crore units. While multiple sources in the provided text use slightly different rounding, they converge on the same outcome: a strong profit increase in Q1 FY27.

EBITDA and margin: absolute gains, slight margin compression

On operating profitability, adjusted EBITDA (excluding forex loss) was reported at ₹454 crore, up 21% from ₹377 crore in Q1 FY26. Separately, EBITDA was also referenced at 4.24B rupees (about ₹424 crore) compared with 3.5B rupees (about ₹350 crore) in the year-ago quarter. Despite the improvement in absolute EBITDA, the EBITDA margin narrowed marginally to 26.1% from 27% in the year-ago quarter, according to the data provided. The combination of higher EBITDA and a slightly lower margin is consistent with a quarter where revenue accelerated faster but the cost base also moved up, or where the product and market mix shifted.

Segment performance: US Generics leads, branded generics steady

Ajanta Pharma’s segment split in the provided text highlights different growth rates across geographies and channels. Branded Generics grew 13% and contributed ₹1,059 crore to total revenue for the quarter. US Generics was the standout with 57% year-on-year growth, generating ₹487 crore. The Africa Institution business saw an 83% jump to ₹70 crore. These figures collectively show that growth was not dependent on a single line item, but the US Generics surge was the most prominent contributor to the overall acceleration.

Interim dividend: ₹32 per share, record date Aug 5

The board approved a first interim dividend of ₹32 per equity share for FY2026-27. The dividend is based on a face value of ₹2 per share, with the total payout stated at approximately ₹399.79 crore. The record date for the dividend is August 5, 2026, and payment is expected on or after August 18, 2026. For shareholders, the key operational takeaway is that the company paired a high-growth quarter with an immediate cash distribution, with specific dates published for eligibility and payment.

Earnings conference call rescheduled to July 30, 2026

Ajanta Pharma also communicated that its Q1 FY27 earnings conference call was rescheduled to July 30, 2026 at 16:15 IST, scheduled for a 16:15 to 17:15 IST slot. The company provided updated dial-in details for domestic and international participants, including universal access numbers and toll-free lines for markets such as the US and UK. A playback was expected to be available 120 minutes after the conclusion of the event. The rescheduled call adds a near-term checkpoint for investors seeking management commentary on the quarter’s drivers, including the strength in US generics and the margin trajectory.

Market snapshot: price, market cap and recent move

The provided data points include multiple market snapshots around the time of the update. One snapshot listed CMP at ₹3,369.5 and market capitalisation at ₹42,097.06 crore. Another set of figures cited a current price of ₹3,330.70 and market cap of ₹41,604.47 crore. A separate close print showed 3,307.60, up 28.80 points or 0.88%. These are point-in-time references rather than a single definitive close, but they indicate that the results and dividend announcement were accompanied by active market attention.

Key numbers at a glance (Q1 FY27 vs Q1 FY26)

The quarter’s core operating and shareholder return metrics can be summarised directly from the disclosed data. Revenue rose to about ₹1,626 crore from about ₹1,303 crore. PAT rose to about ₹334 crore from about ₹255 crore. Adjusted EBITDA (excluding forex loss) increased to ₹454 crore from ₹377 crore. Reported EBITDA was also described at about ₹424 crore versus about ₹350 crore, with margin easing to 26.1% from 27%.

Why the update matters for investors

The Q1 FY27 results matter because they combine strong top-line momentum with a faster rise in profit, which typically signals favourable product mix and execution. The stated 57% year-on-year growth in US Generics is particularly relevant because the US business can be sensitive to competition and pricing, making such an expansion a key quarterly marker. At the same time, the slight narrowing in EBITDA margin to 26.1% from 27% provides a reminder that growth does not always translate into expanding margins every quarter. The ₹32 per share interim dividend, totalling about ₹399.79 crore, adds a concrete shareholder return element to the earnings release, with clear record and payment dates.

Conclusion

Ajanta Pharma’s Q1 FY27 performance showed revenue rising to about ₹1,626 crore and PAT increasing to about ₹334 crore, supported by a sharp step-up in US Generics and steady branded generics growth. The board’s first interim dividend of ₹32 per share, with a record date of August 5, 2026 and payment expected on or after August 18, 2026, sets the next timeline for shareholders. The earnings conference call on July 30, 2026 at 16:15 IST is the immediate next event where investors can track management’s commentary on the quarter’s drivers and profitability trend.